These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

427 related articles for article (PubMed ID: 27456066)

  • 21. Pharmacokinetics, pharmacodynamics and clinical efficacy of non-statin treatments for hypercholesterolemia.
    Cicero AFG; Bove M; Borghi C
    Expert Opin Drug Metab Toxicol; 2018 Jan; 14(1):9-15. PubMed ID: 29231064
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Poststatin Lipid Therapeutics: A Review.
    Jia X; Lorenz P; Ballantyne CM
    Methodist Debakey Cardiovasc J; 2019; 15(1):32-38. PubMed ID: 31049147
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of add on therapies in patients with hypercholesterolemia undergoing statin therapy.
    Tomlinson B; Chan P; Zhang Y; Lam CWK
    Expert Opin Pharmacother; 2020 Dec; 21(17):2137-2151. PubMed ID: 32772741
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A 10-year experience using combined lipid-lowering pharmacotherapy in children and adolescents.
    Araujo MB; Pacce MS
    J Pediatr Endocrinol Metab; 2016 Nov; 29(11):1285-1291. PubMed ID: 27718491
    [TBL] [Abstract][Full Text] [Related]  

  • 25. How many familial hypercholesterolemia patients are eligible for PCSK9 inhibition?
    Masana L; Plana N; Pérez-Calahorra S; Ibarretxe D; Lamiquiz-Moneo I; Pedro-Botet J; Suárez-Tembra M; Valdivielso P; Ortega E; Civeira F;
    Atherosclerosis; 2017 Jul; 262():107-112. PubMed ID: 28531826
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Eligibility for PCSK9 treatment in 734 Hypercholesterolemic patients referred to a regional cholesterol treatment center with LDL cholesterol ≥ 70 mg/dl despite maximal tolerated cholesterol lowering therapy.
    Glueck CJ; Shah P; Goldenberg N; Prince M; Lee K; Jetty V; Kumar A; Goldenberg M; Wang P
    Lipids Health Dis; 2016 Mar; 15():55. PubMed ID: 26968977
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An updated review of lipid-modifying therapy.
    Simons LA
    Med J Aust; 2019 Jul; 211(2):87-92. PubMed ID: 31006138
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Current treatment of dyslipidaemia: PCSK9 inhibitors and statin intolerance.
    Koskinas K; Wilhelm M; Windecker S
    Swiss Med Wkly; 2016; 146():w14333. PubMed ID: 27400448
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial.
    Sullivan D; Olsson AG; Scott R; Kim JB; Xue A; Gebski V; Wasserman SM; Stein EA
    JAMA; 2012 Dec; 308(23):2497-506. PubMed ID: 23128163
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of the Potential Role of Alirocumab in the Management of Hypercholesterolemia in Patients with High-Risk Cardiovascular Disease.
    Okere AN; Serra C
    Pharmacotherapy; 2015 Aug; 35(8):771-9. PubMed ID: 26256279
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Alirocumab: First Global Approval.
    Markham A
    Drugs; 2015 Sep; 75(14):1699-705. PubMed ID: 26370210
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Statin combination therapy and cardiovascular risk reduction.
    Toth PP; Farnier M; Tomassini JE; Foody JM; Tershakovec AM
    Future Cardiol; 2016 May; 12(3):289-315. PubMed ID: 27079178
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Unmet Need for Further LDL-C Lowering in India despite Statin Therapy: Lipid Association of India Recommendations for the Use of Bempedoic Acid.
    Mehta V; Puri R; Duell PB; Iyengar SS; Wong ND; Yusuf J; Mukhopadhyay S; Pradhan A; Muruganathan A; Wangnoo SK; Kapoor D; Rastogi A; Tiwaskar MH; Mahajan K; Narasingan SN; Agarwala R; Bordoloi N; Soumitra K; Chakraborty R; Shetty S; Saboo B; Khan A; Prabhakar D; Khanna NN; Mehta A; Bansal M; Kasliwal R; Mehrotra R; Chag M; Sheikh A; Sattur GB; Manoria PC; Pareek KK; Pancholia AK; Melinker RP; Nanda R; Kalra D
    J Assoc Physicians India; 2022 Sep; 70(9):11-12. PubMed ID: 36082889
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Therapeutic practice patterns related to statin potency and ezetimibe/simvastatin combination therapies in lowering LDL-C in patients with high-risk cardiovascular disease.
    Toth PP; Foody JM; Tomassini JE; Sajjan SG; Ramey DR; Neff DR; Tershakovec AM; Hu XH; Tunceli K
    J Clin Lipidol; 2014; 8(1):107-16. PubMed ID: 24528691
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evolocumab: A Review in Hyperlipidemia.
    Keating GM
    Am J Cardiovasc Drugs; 2016 Feb; 16(1):67-78. PubMed ID: 26643308
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of Ezetimibe Alone or in Addition to a Statin on Plasma PCSK9 Concentrations in Patients with Type 2 Diabetes and Hypercholesterolemia: A Pilot Study.
    Miyoshi T; Nakamura K; Doi M; Ito H
    Am J Cardiovasc Drugs; 2015 Jun; 15(3):213-9. PubMed ID: 25896669
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Resistance and intolerance to statins.
    Reiner Z
    Nutr Metab Cardiovasc Dis; 2014 Oct; 24(10):1057-66. PubMed ID: 24996502
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evolocumab in the treatment of dyslipidemia: pre-clinical and clinical pharmacology.
    Page MM; Watts GF
    Expert Opin Drug Metab Toxicol; 2015; 11(9):1505-15. PubMed ID: 26293511
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [ACUTE CORONARY SYNDROME AND LIPID-LOWERING THERAPY. DOES THE IMPROVE-IT STUDY MAKE ANY DIFFERENCE?].
    Lancellotti P; Pierard LA; Scheen AJ
    Rev Med Liege; 2015 Sep; 70(9):450-5. PubMed ID: 26638446
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.